Pregnancy outcome after cabergoline treatment in early weeks of gestation

Elena Ricci, Fabio Parazzini, Tiziano Motta, Carlo I. Ferrari, Annamaria Colao, Antonio Clavenna, Francesca Rocchi, Emanuela Gangi, Sandra Paracchi, Maurizio Gasperi, Maurizio Lavezzari, Anna Elisa Nicolosi, Simona Ferrero, Maria Luisa Landi, Paolo Beck-Peccoz, Maurizio Bonati

Research output: Contribution to journalArticlepeer-review


We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies resulted in 12 (19.7%) early terminations (five induced abortions, six spontaneous abortions, one hydatidiform mole) and 49 (80.3%) live births. In one case, malformations were suspected by a gynecologist based on ultrasound at 12 gestational weeks and the pregnancy was terminated; additional information was not available. There was one case of trisomy 18. The frequency of spontaneous and induced abortions and major congenital malformations was comparable with rates in the general population. The data did not indicate any potential adverse effect of the drug on pregnancy. The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.

Original languageEnglish
Pages (from-to)791-793
Number of pages3
JournalReproductive Toxicology
Issue number6
Publication statusPublished - Nov 2002


  • Cabergoline
  • Drug adverse effects
  • Newborn
  • Pregnancy

ASJC Scopus subject areas

  • Toxicology


Dive into the research topics of 'Pregnancy outcome after cabergoline treatment in early weeks of gestation'. Together they form a unique fingerprint.

Cite this